Patient Perceptions and Quality of Life Associated With the Use of Olapatadine 0.2% for the Treatment of Allergic Conjunctivitis

The purpose of this study is to evaluate patient perceptions of olopatadine 0.2% dosed once daily in patients previously treated with twice-daily, topical, ocular, anti-allergy medications.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Allergic Conjunctivitis Conjunctival Diseases Conjunctivitis Conjunctivitis, Allergic Eye Diseases Hypersensitivity Hypersensitivity, Immediate Immune System Diseases

Age range

12 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

12 years of age or older.
History (within the past 24 months) of allergic conjunctivitis.
Active signs and symptoms of ocular allergies.
Ocular health within normal limits, as determined by the investigator or subinvestigator.
Willing to avoid contact lens wear each study visit immediately prior to study medication instillation and for 10 minutes after instillation of study drug.
Other protocol-defined inclusion criteria may apply.

Exclusion criteria

Contraindications or hypersensitivity to study medication or its components.
One sighted eye or not correctable to 0.6 logMAR or better in both eyes at the screening visit.
Known history of recurrent corneal erosion syndrome.
Ocular trauma or surgical intervention within 6 months prior to Visit 1.
Participation in any other investigational study within 30 days before Visit 1.
Pregnant or nursing.
Other protocol-defined exclusion criteria may apply.

Treatment and study plan

Olopatadine hydrochloride ophthalmic solution, 0.2% (Pataday®)

Drug

Commercially marketed ophthalmic solution for the treatment of ocular itching associated with allergic conjunctivitis

Other names: Pataday®

Primary outcomes

Overall Patient Satisfaction

Time frame: Day 0

Overall satisfaction was assessed by the patient on a questionnaire. The patient was instructed to select a single response to the statement, "Overall, how satisfied are you with your current eye allergy medication?" A 5-point scale was used: very satisfied, satisfied, undecided, dissatisfied, very dissatisfied. Results are reported as the percentage of patients who responded, "very satisfied" or "satisfied."
Overall Patient Satisfaction

Time frame: Day 7

Overall satisfaction was assessed by the patient on a questionnaire. The patient was instructed to select a single response to the statement, "Overall, how satisfied were you with olopatadine 0.2%?" A 5-point scale was used: very satisfied, satisfied, undecided, dissatisfied, very dissatisfied. Results are reported as the percentage of patients who responded, "very satisfied" or "satisfied."

Sponsors and collaborators

Lead sponsor

Alcon Research

Industry

Registry information

Important dates

Study start: 2010
Primary completion: 2010
Study completion: 2010
First posted: Jul 9, 2010
Registry last updated: Apr 3, 2012

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed